Medicine:Peginterferon alfa-2a

From HandWiki
Short description: Pharmaceutical drug
Peginterferon alfa-2a
Clinical data
Trade namesPegasys, others
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa605029
License data
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC860H1353N227O255S9
Molar mass19 241 g·mol−1 (unpegylated)
40 000 g/mol (pegylated)
 ☒N☑Y (what is this?)  (verify)

Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B.[1] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%.[1][2] For hepatitis B it may be used alone.[3] It is given by injection under the skin.[1]

Side effects are common.[4] They may include headache, feeling tired, depression, trouble sleeping, hair loss, nausea, pain at the site of injection, and fever.[1] Severe side effects may include psychosis, autoimmune disorders, blood clots, or infections.[1] Use with ribavirin is not recommended during pregnancy.[1] Pegylated interferon alfa-2a is in the alpha interferon family of medications.[1] It is pegylated to protect the molecule from breakdown.[4]

Pegylated interferon alfa-2a was approved for medical use in the United States in 2002.[1] It is on the World Health Organization's List of Essential Medicines.[5]

Medical uses

This drug is approved around the world for the treatment of chronic hepatitis C (including people with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, United States , China and many other countries) for the treatment of chronic hepatitis B. It is also used in the treatment of certain T-cell lymphomas, particularly mycosis fungoides.[citation needed]

Peginterferon alfa-2a is a long acting interferon. Interferons are proteins released in the body in response to viral infections. Interferons are important for fighting viruses in the body, for regulating reproduction of cells, and for regulating the immune system.[6]

Host genetic factors

For genotype 1 hepatitis C treated with pegylated interferon alfa-2a or pegylated interferon alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature,[7] showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Another report in Nature demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.[8]

Manufacturing

It is pegylated with a branched 40 kg/mol PEG chain.[9]

Society and culture

Availability

Peginterferon alfa-2a is manufactured under the brand name Pegasys. In 2021, Roche Pharmaceuticals sold the worldwide rights of Pegasys (excluding China and Japan) to zr pharma& GmbH (pharma&).[10][11][12][13][14] In May 2022, Roche Australia transferred the sales and marketing of Pegasys to Echo Therapeutics Pty Ltd.[15]

Research

A Cochrane Review sought to determine whether interferon alfa-2a could be used as a treatment for individuals with neovascular age-related macular degeneration. They found no evidence of improved visual acuity with potential harm.[16]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Peginterferon Alfa-2a (Professional Patient Advice) - Drugs.com". https://www.drugs.com/ppa/peginterferon-alfa-2a.html. 
  2. ↑ "Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC)". https://www.medicines.org.uk/emc/medicine/32432. 
  3. ↑ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 639. ISBN 9780857111562. 
  4. ↑ 4.0 4.1 "Peginterferon alfa-2a (Pegasys) - Treatment - Hepatitis C Online". http://www.hepatitisc.uw.edu/page/treatment/drugs/peginterferon-alfa-drug. 
  5. ↑ World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO. 
  6. ↑ "Interferon alfa-2a Uses, Side Effects & Warnings" (in en). https://www.drugs.com/mtm/interferon-alfa-2a.html. 
  7. ↑ "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature 461 (7262): 399–401. 2009. doi:10.1038/nature08309. PMID 19684573. Bibcode: 2009Natur.461..399G. 
  8. ↑ "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature 461 (7265): 798–801. 2009. doi:10.1038/nature08463. PMID 19759533. Bibcode: 2009Natur.461..798T. 
  9. ↑ "Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C". Advanced Drug Delivery Reviews 54 (4): 571–86. June 2002. doi:10.1016/s0169-409x(02)00028-5. PMID 12052715. 
  10. ↑ "Pegasys (peginterferon alfa-2a)". https://www.gene.com/patients/medicines/pegasys. 
  11. ↑ "Verzichtserklärung der Zulassung - Mittelfristig läuft Pegasys aus". https://assets.cwp.roche.com/f/94122/x/2b0bc67a9f/mittelfristig-luft-pegasys-aus-original-1176.pdf. 
  12. ↑ "Pegasys (Peginterferon alfa-2a) langfristig weiterhin erhältlich" (in de). https://assets.cwp.roche.com/f/94122/x/8f2de3daec/kurzmeldung-pegasys-bleibt-verfugbar.pdf. 
  13. ↑ "pharma& portfolio". https://www.pharmaand.com/portfolio-rx. 
  14. ↑ "HALF-YEAR REPORT 2021, p.20". https://www.roche.com/dam/jcr:7260c9fc-2310-4305-bc10-ca3cea0de87d/en/hy21e.pdf. 
  15. ↑ "Pegasys". https://www.roche-australia.com/en_au/products/pharmaceuticals/pegasys.html. 
  16. ↑ "Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration". Cochrane Database Syst Rev 1 (1): CD005138. 2006. doi:10.1002/14651858.CD005138.pub2. PMID 16437522. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Peginterferon_alfa-2a&oldid=3669184"